Table 3.
a) Patel criteria (Clinically localized, Gleason score ≤ 7, and no significant comorbidities) | |||
---|---|---|---|
HR | 95% CI | p-value | |
Age (yrs) | 1.01 | 1.00–1.02 | 0.17 |
PSA (ng/ml) | 1.04 | 1.03–1.04 | <0.0001 |
Gleason > 6 | 2.74 | 2.27–3.32 | <0.0001 |
Clinical Stage T2 vs. T1 | 1.89 | 1.56–2.30 | <0.0001 |
b) Choo criteria (T1b-T2b N0M0, Gleason score ≤ 7, and PSA ≤ 15 ng/ml | |||
---|---|---|---|
HR | 95% CI | p-value | |
Age (yrs) | 1.00 | 0.99–1.02 | 0.68 |
PSA (ng/ml) | 1.15 | 1.12–1.19 | <0.0001 |
Gleason > 6 | 2.87 | 2.30–3.58 | <0.0001 |
Clinical Stage T2 vs. T1 | 1.92 | 1.55–2.38 | <0.0001 |
c) Mohler criteria (T1c PCa) | |||
---|---|---|---|
HR | 95% CI | p-value | |
Age (yrs) | 1.01 | 0.99–1.03 | 0.44 |
PSA (ng/ml) | 1.06 | 1.04–1.07 | <0.0001 |
Gleason > 6 | 3.19 | 2.35–4.35 | <0.0001 |